Introduction
et al. demonstrated that haemodialysis patients with their native kidneys still present had elevated MSNA. We have recently shown that sympathetic activity is
In contrast, in bilaterally nephrectomized patients, increased in patients with chronic renal failure (CRF ),
MSNA was identical to that in healthy controls [6 ] . and that this can be controlled by enalapril, but not This suggests strongly that the signal commanding the by amlodipine [1] . What can we learn from these data brain to increase sympathetic outflow is generated in and do they affect our daily clinical practice? the diseased kidneys. We confirmed this observation in a larger group of hypertensive CRF patients not yet on dialysis, and were able to add that baroreflex
Sympathetic overactivity in CRF
sensitivity was not altered in these patients [1] . We also found recently that MSNA is elevated in hyperIs it news that sympathetic activity is high in patients tensive patients with polycystic kidney disease but still with CRF? Certainly not. The subject was recently normal renal function [7] . reviewed in this journal and elsewhere [2, 3] , although the information that we had until recently was quite indirect. It was known for a long time that plasma Pathophysiology of sympathetic overactivity in catecholamine concentrations are approximately doubled in CRF patients [4, 5] , but this could also be CRF due to the reduced clearance of catecholamines by the kidney. Although the method of measuring muscle Is it surprising that sympathetic activity is increased sympathetic nerve activity (MSNA) directly in humans in CRF? No. Experimental studies have come up was available in the late seventies, the first publication with at least two pathophysiological mechanisms. showing that MSNA was increased in CRF patients Inappropriate renin secretion in relation to the state of sodium-volume balance has long been recognized Correspondence and offprint requests to: Peter J. Blankestijn, [8, 9] . The renin output of the kidney is the sum of the Department of Nephrology and Hypertension, University Medical production of all nephrons. If all nephrons of the Center Utrecht, PO Box 85500, NL-3508 GA Utrecht, The Netherlands. diseased kidneys were affected equally and secrete equal amounts of renin, CRF would be characterized sympathetic outflow. ACE inhibition eliminates angiotensin II stimulatory effects on the central nervous as a new steady state with high blood pressure and normal renin. The concept of 'nephron heterogeneity' system by blocking its generation. By improving renal perfusion and decreasing ischaemia, it can also lessen stands for the hypothesis that the nephrons are not equally affected by the disease. Those that are severely the stimulatory effects of the renal afferent nerves.
However, our finding that amlodipine, which can also affected hypofilter, showing impaired sodium excretion and renin hypersecretion, whereas those less affected increase renal perfusion, did not reduce MSNA, suggests major importance for the former mechanism. will adapt to the elevated blood pressure by hyperfiltration and suppression of renin secretion. Blood
In chronic heart failure, a disease state also characterized by high renin levels and high MSNA, chronic pressure will not be high enough to suppress renin production in all nephrons. As a result CRF is usually ACE inhibition also reduces sympathetic overactivity [18] . In this patient group baroreceptor sensitivity, characterized by high blood pressure and high renin.
High circulating angiotensin II concentrations have which is impaired, improves during ACE inhibition treatment. The mechanism is unclear. In CRF patients, a variety of effects. Angiotensin II has direct vasoconstricting properties, increases aldosterone production, baroreceptor sensitivity is not different from controls and is not affected by ACE inhibition [1] . Traditional and has trophic effects. There is clear evidence that angiotensin II stimulates central sympathetic outflow sympatholytic drugs often reduce baroreceptor sensitivity, resulting in orthostatic hypotension. by a direct effect on the vasomotor centres in the brain stem [10] , which can be picked up as increased MSNA
In patients with essential hypertension and normal renin activity, chronic ACE inhibition reduces blood [11] . Angiotensin II enhances sympathetic activity also at peripheral sites. Angiotensin II enhances noradren-pressure but does not affect MSNA [19] . Apparently, sympathetic suppression by ACE inhibition occurs aline release through a presynaptic effect on peripheral nerves [12] . This cannot be picked up by MSNA.
only if the renin-angiotensin system is stimulated. Put together, these observations indicate that ACE inhib-A second way by which the kidneys can command the brain to increase sympathetic outflow is increased itors are not sympatholytic drugs per se, but modulate basal activity of the brain centres responsible for the renal afferent nerve activity. This is started by renal ischaemia. During renal ischaemia, adenosine is regulation of central sympathetic outflow.
Whether angiotensin II receptor antagonists can also released. This adenosine evokes an increase in afferent renal nerve traffic, as can be shown during adenosine control sympathetic overactivity has not yet been studied. Crucial is that such drugs can penetrate into infusion in the renal artery of uninephrectomized dogs [13] . Such infusion also causes an increase in blood the brain centres involved in regulating sympathetic outflow. As recently put forward in this journal, the pressure, which is prevented by renal denervation [13] . In rats, induction of renal artery stenosis [14] , partial net effect of these drugs on peripheral sympathetic activity may be even larger than that of ACE inhibition renal ablation by arterial ligation [15] , or intrarenal phenol injection [16 ] , cause excitation of the renal [12] . First, ACE inhibition cannot completely prevent formation of angiotensin II, whereas receptor antagonafferent nerves. This results in an increase in central sympathetic outflow and hypertension. In these animal ists may completely block the actions of angiotensin II.
Second, stimulation of bradykinin formation by ACE models, bilateral renal afferent denervation prevents the increase in blood pressure.
inhibition may facilitate noradrenaline release by sympathetic nerves [12] . However, the clinical relevance Since both mechanisms underlying the sympathetic stimulation, i.e. increased angiotensin II levels and of such a difference may be difficult to prove. renal afferent nerve traffic, are related to intrarenal ischaemia, it is difficult to differentiate between contriClinical importance of control of sympathetic bution of these two mechanisms in human disease. For overactivity example, in patients with renovascular hypertension MSNA is also high, and restored by arterial recanalization [17] . In such cases it is likely that both ischaemia-Is it important to control sympathetic overactivity in patients with renal failure? Yes, we think so. First, induced renal afferent nerve activity and angiotensin II release are relevant. Whether this also holds good for sympathetic overactivity contributes to the hypertension in CRF patients. This was clearly demonstrated more complex renal disease states such as glomerulonephritis or polycystic kidney disease is unclear.
by Schohn et al. [20] , who found a profound decline in blood pressure after the ganglion blocker debrisoquine in hypertensive haemodialysis patients, but
How can ACE inhibition lower sympathetic
only a moderate effect in normotensive patients. We activity?
also found an exaggerated blood pressure response to the sympatholytic drug clonidine in CRF patients [1] . Second, sympathetic overactivity may increase the risk Is it surprising that ACE inhibition can decrease the sympathetic overactivity in renal failure? We think of developing cardiovascular disease. There is evidence that sympathetic activity contributes to the genesis of not. With the two pathophysiological mechanisms described in the previous paragraph in mind, it is in structural changes, including left ventricular hypertrophy and arteriolar remodelling, independent of its fact logical that ACE inhibition reduces central hypertensive action [21, 22] . Treatment aimed at regres-References sion of these abnormalities is particularly successful to be studied. 
